<clinical_study>
  <!-- This xml conforms to an XML Schema at:
    https://clinicaltrials.gov/ct2/html/images/info/public.xsd -->
  <required_header>
    <download_date>ClinicalTrials.gov processed this data on November 19, 2021</download_date>
    <link_text>Link to the current ClinicalTrials.gov record.</link_text>
    <url>https://clinicaltrials.gov/show/NCT01719016</url>
  </required_header>
  <id_info>
    <org_study_id>10-05-05-02</org_study_id>
    <nct_id>NCT01719016</nct_id>
  </id_info>
  <brief_title>Improvement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid Dynamics</brief_title>
  <official_title>Improvement Assessment of Coronary Flow Dysfunction Using Fundamental Fluid Dynamics</official_title>
  <sponsors>
    <lead_sponsor>
      <agency>University of Cincinnati</agency>
      <agency_class>Other</agency_class>
    </lead_sponsor>
  </sponsors>
  <source>University of Cincinnati</source>
  <oversight_info>
    <has_dmc>No</has_dmc>
  </oversight_info>
  <brief_summary>
    <textblock>
      Diagnosis of relative contributions of large artery blockages and microvascular blockages is&#xD;
      very much needed in the treatment of coronary artery disease. In order to achieve this, two&#xD;
      novel parameters, pressure drop coefficient (CDP), which combines flow and pressure readings&#xD;
      and Lesion flow coefficient (LFC), which combines anatomical details of the lesion with&#xD;
      pressure and flow readings, are being investigated.&#xD;
    </textblock>
  </brief_summary>
  <detailed_description>
    <textblock>
      Diagnosis of relative contributions of large artery blockages and microvascular blockages is&#xD;
      very much needed in the treatment of coronary artery disease. In order to achieve this, two&#xD;
      novel parameters, pressure drop coefficient (CDP), which combines flow and pressure readings&#xD;
      and Lesion flow coefficient (LFC), which combines anatomical details of the lesion with&#xD;
      pressure and flow readings, are being investigated. The diagnostic parameters will be&#xD;
      correlated with Coronary Flow Reserve (CFR)values obtained using Positron Emission Tomography&#xD;
      (PET) imaging. They will also be correlated with Fractional Flow Reserve (FFR).&#xD;
    </textblock>
  </detailed_description>
  <overall_status>Active, not recruiting</overall_status>
  <start_date>August 2010</start_date>
  <completion_date type="Anticipated">June 30, 2022</completion_date>
  <primary_completion_date type="Anticipated">June 30, 2022</primary_completion_date>
  <study_type>Observational</study_type>
  <has_expanded_access>No</has_expanded_access>
  <study_design_info>
    <observational_model>Other</observational_model>
    <time_perspective>Prospective</time_perspective>
  </study_design_info>
  <primary_outcome>
    <measure>Quantification of relative contributions of large artery disease and microvascular disease</measure>
    <time_frame>2 years</time_frame>
    <description>Correlation Coronary Flow Reserve (CFR) from Positron Emission Tomography (PET)imaging with diagnostic parameters, Pressure Drop Coefficient (CDP) and Lesion Flow Coefficient (LFC).</description>
  </primary_outcome>
  <secondary_outcome>
    <measure>Quantification of relative contributions of large artery disease and microvascular disease</measure>
    <time_frame>2 years</time_frame>
    <description>Correlation of CDP and LFC with invasively measured Fractional Flow Reserve (FFR) values.</description>
  </secondary_outcome>
  <number_of_groups>1</number_of_groups>
  <enrollment type="Actual">68</enrollment>
  <condition>Coronary Artery Disease</condition>
  <arm_group>
    <arm_group_label>Cardiac PET, Coronary catheterization</arm_group_label>
    <description>Cardiac PET scan:&#xD;
Injection of N-13 Ammonia radionuclide. 2 doses of 10 milliCuries and 20 milliCuries each.&#xD;
Injection of Lexiscan.&#xD;
Coronary catheterization:&#xD;
Pressure and flow readings using Combowire&#xD;
Injection of Adenosine.</description>
  </arm_group>
  <intervention>
    <intervention_type>Procedure</intervention_type>
    <intervention_name>Cardiac PET, Coronary catheterization</intervention_name>
    <description>Patients would under go a Cardiac rest and stress PET scan and include the following drug administration:&#xD;
N-13 Ammonia radionuclide - Two doses, 10 mCi for rest, 20 mCi for stress&#xD;
Lexiscan - stress agent for PET scan&#xD;
Patients would also undergo Coronary catheterization including the following drug administration and device usage:&#xD;
Combowire to obtain pressure and flow readings on Combomap machine (Volcano Therapeutics, CA).&#xD;
Adenosine - stress agent during catheterization, 140 ug/Kg/min</description>
    <arm_group_label>Cardiac PET, Coronary catheterization</arm_group_label>
    <other_name>Volcano therapeutics</other_name>
    <other_name>Combomap machine</other_name>
    <other_name>Adenosine</other_name>
    <other_name>Lexiscan</other_name>
    <other_name>N-13 Ammonia</other_name>
  </intervention>
  <eligibility>
    <study_pop>
      <textblock>
        Patients with chest pain and suspected ischemia that needs to be assessed by a stress test&#xD;
      </textblock>
    </study_pop>
    <sampling_method>Probability Sample</sampling_method>
    <criteria>
      <textblock>
        Inclusion Criteria:&#xD;
&#xD;
          -  18 years of age or above&#xD;
&#xD;
          -  Patients referred to a stress test by a Cardiologist&#xD;
&#xD;
          -  Acute Chest pain, as per patient input.&#xD;
&#xD;
          -  Risk Assessment with prior test results and/or previous history of known chronic&#xD;
             stable CAD.&#xD;
&#xD;
          -  Borderline or discordant stress testing where obstructive CAD remains a concern.&#xD;
&#xD;
          -  New or worsening symptoms- Abnormal coronary angiography or abnormal prior stress&#xD;
             imaging study.&#xD;
&#xD;
          -  Coronary stenosis or anatomic abnormality of uncertain significance.&#xD;
&#xD;
          -  In absence of reliable diagnostic information from another imaging modality.&#xD;
&#xD;
        Exclusion Criteria:&#xD;
&#xD;
          -  Left ventricular ejection fraction less the 25% determined by gated SPECT imaging&#xD;
&#xD;
          -  Non-dialysis dependent chronic kidney disease with baseline serum creatinine greater&#xD;
             than 2.5 gm/dL.&#xD;
&#xD;
          -  History of type II heparin-induced thrombocytopenia.&#xD;
&#xD;
          -  Significant co-morbid condition that is medically unstable and would make coronary&#xD;
             angiography prohibitive or contraindicated.&#xD;
&#xD;
          -  Pregnant women.&#xD;
&#xD;
          -  Incapacitated for Consent&#xD;
      </textblock>
    </criteria>
    <gender>All</gender>
    <minimum_age>18 Years</minimum_age>
    <maximum_age>100 Years</maximum_age>
    <healthy_volunteers>No</healthy_volunteers>
  </eligibility>
  <overall_official>
    <last_name>Rupak K Banerjee, PhD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati , CVAMC</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Mohamed Effat, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>Univesity of Cincinnati, University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Imran Arif, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati and University Hospital</affiliation>
  </overall_official>
  <overall_official>
    <last_name>Hanan Kerr, MD</last_name>
    <role>Principal Investigator</role>
    <affiliation>University of Cincinnati</affiliation>
  </overall_official>
  <location>
    <facility>
      <name>Cincinnati Veteran Affairs Medical Center</name>
      <address>
        <city>Cincinnati</city>
        <state>Ohio</state>
        <zip>45220</zip>
        <country>United States</country>
      </address>
    </facility>
  </location>
  <location_countries>
    <country>United States</country>
  </location_countries>
  <verification_date>April 2021</verification_date>
  <study_first_submitted>October 29, 2012</study_first_submitted>
  <study_first_submitted_qc>October 31, 2012</study_first_submitted_qc>
  <study_first_posted type="Estimate">November 1, 2012</study_first_posted>
  <last_update_submitted>April 28, 2021</last_update_submitted>
  <last_update_submitted_qc>April 28, 2021</last_update_submitted_qc>
  <last_update_posted type="Actual">April 30, 2021</last_update_posted>
  <responsible_party>
    <responsible_party_type>Principal Investigator</responsible_party_type>
    <investigator_affiliation>University of Cincinnati</investigator_affiliation>
    <investigator_full_name>Rupak K. Banerjee</investigator_full_name>
    <investigator_title>Professor</investigator_title>
  </responsible_party>
  <keyword>Reversible ischemia</keyword>
  <keyword>microvascular dysfunction</keyword>
  <condition_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Coronary Artery Disease</mesh_term>
  </condition_browse>
  <intervention_browse>
    <!-- CAUTION:  The following MeSH terms are assigned with an imperfect algorithm            -->
    <mesh_term>Adenosine</mesh_term>
  </intervention_browse>
  <patient_data>
    <sharing_ipd>Undecided</sharing_ipd>
  </patient_data>
  <!-- Results have not yet been posted for this study                                          -->
</clinical_study>

